Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EBT: 2012-2025

Historic EBT for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$18.7 million.

  • Enanta Pharmaceuticals' EBT rose 36.04% to -$18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.5 million, marking a year-over-year increase of 29.07%. This contributed to the annual value of -$83.5 million for FY2025, which is 29.07% up from last year.
  • Enanta Pharmaceuticals' EBT amounted to -$18.7 million in Q3 2025, which was down 2.43% from -$18.2 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' EBT registered a high of -$18.2 million during Q2 2025, and its lowest value of -$37.6 million during Q1 2023.
  • In the last 3 years, Enanta Pharmaceuticals' EBT had a median value of -$29.2 million in 2024 and averaged -$27.6 million.
  • Its EBT has fluctuated over the past 5 years, first plummeted by 193.75% in 2021, then spiked by 36.04% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' EBT (Quarterly) stood at -$30.2 million in 2021, then grew by 3.75% to -$29.0 million in 2022, then decreased by 17.26% to -$34.0 million in 2023, then skyrocketed by 33.27% to -$22.7 million in 2024, then spiked by 36.04% to -$18.7 million in 2025.
  • Its EBT was -$18.7 million in Q3 2025, compared to -$18.2 million in Q2 2025 and -$23.9 million in Q1 2025.